Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder

First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+

AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer

Combination shows consistent benefit across prespecified post-progression outcomes

Merck invests € 300 million in new Life Science production site in South Korea

New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics

Celanese and Secarna Pharmaceuticals collaborate for RNA research for antisense therapies

Venus Remedies secures regulatory approvals for three key oncology drugs in Ukraine

Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy

Sun Pharmaceuticals receives approval for Winlevi in Australia

Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older

AstraZeneca to acquire Amolyt Pharma

Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition

CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product

Successful use of Zidebactam/Cefepime to treat skull bone infection & pneumonia caused by extreme-drug resistant pseudomonas

With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained

USFDA grants Orphan Drug Designation for iOnctura's first-in-class autotaxin cancer therapy

It is the first autotaxin inhibitor to be investigated in cancer patients